Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Shandong Xinhua Pharmaceutical Company Limited Class H ( (HK:0719) ) has shared an update.
Shandong Xinhua Pharmaceutical Company Limited announced that its Tramadol Hydrochloride Sustained-release Tablets have passed the Consistency of Quality and Efficacy Evaluation for Generic Drugs by the National Medical Products Administration. This approval marks the company as the first domestic enterprise to achieve this milestone for the product, potentially enhancing its market competitiveness and stakeholder confidence.
More about Shandong Xinhua Pharmaceutical Company Limited Class H
Shandong Xinhua Pharmaceutical Company Limited operates in the pharmaceutical industry, focusing on the production and distribution of generic drugs. The company is a leading pharmaceutical enterprise in China, known for manufacturing prescription drugs, including Tramadol Hydrochloride Sustained-release Tablets, and has a strong presence in the domestic market.
YTD Price Performance: -1.89%
Average Trading Volume: 3,144,483
Technical Sentiment Consensus Rating: Sell
Current Market Cap: HK$10.01B
Find detailed analytics on 0719 stock on TipRanks’ Stock Analysis page.
